Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Operating Leases: 2019-2024

Historic Operating Leases for Syndax Pharmaceuticals (SNDX) over the last 6 years, with Dec 2024 value amounting to $2.0 million.

  • Syndax Pharmaceuticals' Operating Leases rose 254.50% to $2.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was $2.0 million, marking a year-over-year increase of 254.50%. This contributed to the annual value of $2.0 million for FY2024, which is 254.50% up from last year.
  • Per Syndax Pharmaceuticals' latest filing, its Operating Leases stood at $2.0 million for FY2024, which was up 254.50% from $578,000 recorded in FY2023.
  • Syndax Pharmaceuticals' Operating Leases' 5-year high stood at $2.0 million during FY2024, with a 5-year trough of $101,000 in FY2020.
  • Moreover, its 3-year median value for Operating Leases was $709,000 (2022), whereas its average is $1.1 million.
  • As far as peak fluctuations go, Syndax Pharmaceuticals' Operating Leases plummeted by 75.89% in 2020, and later spiked by 603.96% in 2021.
  • Over the past 5 years, Syndax Pharmaceuticals' Operating Leases (Yearly) stood at $101,000 in 2020, then spiked by 603.96% to $711,000 in 2021, then decreased by 0.28% to $709,000 in 2022, then fell by 18.48% to $578,000 in 2023, then soared by 254.50% to $2.0 million in 2024.